

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Satoshi TAKEO et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2006_0437A
Filed April 13, 2006 :

AGENT FOR IMPROVING MENTAL DISORDERS
[Corresponding to PCT/JP2004/011696
Filed August 13, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication;
- each reference previously cited in the international application PCT/JP2004/011696; and/or
- each reference previously cited in prior parent application Serial No. _____.

1a. This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. This Information Disclosure Statement is submitted
after the events of above paragraph 1a and prior to the mailing date of a final Office
Action or a Notice of Allowance or an action which otherwise closes prosecution in the
application, and thus:

- (1) the certification of paragraph 2 below is provided, **or**
- (2) the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. This Information Disclosure Statement is submitted:
after the mailing date of a final Office Action or Notice of Allowance or action which
otherwise closes prosecution in the application, and prior to payment of the issue fee, and
thus:

the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified
 - a. that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
 - b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
3. Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. a full or partial English language translation submitted herewith,
 - b. a foreign patent office search report (in the English language) submitted herewith,
 - c. the concise explanation contained in the specification of the present application at page,
 - d. the concise explanation set forth in the attached English language abstract,
 - e. the concise explanation set forth below or on a separate sheet attached to the reference:
5. A foreign patent office search report citing one or more of the references is enclosed.
6. Also enclosed is a Declaration of Satoshi TAKEO, Keiko TAKAGI, Nori TAKAGI and Toshikazu NAKAMURA, dated November 5, 2003, together with a copy of their publication "Cerebroprotective effects of hepatocyte growth factor against ischemic brain injury", Seikagaku, Vol. 75, No. 8, p. 774, August 25, 2003 in Japanese with its English translation.

There is also enclosed a Declaration of Ichiro DATE and Makiko NIIMURA dated November 6, 2003 confirming that they are experimental collaborators for the authors and inventors. Thus it is submitted that the cited Reference AL is a publication of the inventors and not prior art.

Respectfully submitted,

Satoshi TAKEO et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
April 13, 2006

Sheet 1 of 2

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: April 13, 2006

ATTY DOCKET NO.
2006_0437ASERIAL NO.
NEW

10/575712

APPLICANT
Satoshi TAKEO et al.FILING DATE
April 13, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-------------------	--	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AA	95/07709	3/1995	WO			Abstract
	AB	7-41429	2/1995	JP			Abstract
	AC	01/21214	3/2001	WO			Abstract
	AD	03/037365	5/2003	WO			
	AE	02/30908	4/2002	WO			
	AF	2003-506368	2/2003	JP			x
	AG	01/09121	2/2001	WO			Corresponds to AF
	AH	97/07824	3/1997	WO			Abstract

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	M. Akimoto et al., "Hepatocyte growth factor enhances spatial learning performance in mice", Society for Neuroscience Abstracts, Vol. 24, Nos. 1-2, p. 687, Abstract No. 269.13, 1998.
	AJ	N. Matsuki et al., "Augmentation of synaptic plasticity by hepatocyte growth factor in the hippocampal Ca1 region", Society for Neuroscience Abstracts, Vol. 26, Nos. 1-2, p. 1115, Abstract No. 420.1, 2000.
	AK	M. Yamada et al., "Signal transduction in hippocampal neurocytes: Possibility of hepatocyte growth factor (HGF) as memory factor", The Federation Meeting of Japan Neuroscience Society (the 24 th) and Japan Society for Neurochemistry (the 44 th), p. 392, September 26-28, 2001, Kyoto (with English translation).
	AL	S. Takeo et al., "Cerebroprotective effects of hepatocyte growth factor against ischemic brain injury", Seikagaku, Vol. 75, No. 8, p. 774, Abstract No. 4S81-5, 2003 (with English translation).
	AM	K. Ryu et al., "Protective effect of hepatocyte growth promoting-factor on pulmonary injury caused by administration of hydrogen peroxide", J. Japan Med. Soc. Biol. Interface, Vol. 31, pp. 11-16, 2000, (with English translation).
	AN	I. Date et al., "HGF protects the brain from ischemic injury", J. Pharmacol. Sci., Vol. 94, Suppl. 1, p. 116P, Abstract No. O-30173, 2004.
	AO	I. Date et al., "Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction", Biochemical and Biophysical Research Communications, Vol. 319, pp. 1152-1158, 2004.

EXAMINER

DATE CONSIDERED

Sheet 2 of 2

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: April 13, 2006

ATTY DOCKET NO.
2006_0437ASERIAL NO.
NEW

10/575712

APPLICANT
Satoshi TAKEO et al.FILING DATE
April 13, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER
INITIALDOCUMENT
NUMBER

DATE

NAME

CLASS

SUBCLASS

FILING DATE IF
APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BA	6,699,837	3/2004	Nakamura			Corresponds to AA
	BB	6,248,722	6/2001	Morishita et al.			Corresponds to AH
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

BI

BJ

BK

BL

BM

BN

BO

EXAMINER

DATE CONSIDERED